Enochian Biosciences, Inc. (ENOB) financial statements (2020 and earlier)

Company profile

Business Address CENTURY CITY MEDICAL PLAZA
SUITE 906 LOS ANGELES, CA 90067
State of Incorp. DE
Fiscal Year End June 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
6/30/2019
6/30/2018
6/30/2017
6/30/2016
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:111215306
Cash and cash equivalents111216406
Other undisclosed cash, cash equivalents, and short-term investments(0) (0)(1)  
Receivables0000  
Prepaid expense00000 
Other undisclosed current assets0 011(1)
Total current assets:111216415
Noncurrent Assets
Operating lease, right-of-use asset2
Property, plant and equipment     0
Intangible assets, net (including goodwill)167167164000
Goodwill121212   
Intangible assets, net (excluding goodwill)155155152000
Deposits noncurrent assets000000
Other undisclosed noncurrent assets   0 (0)
Total noncurrent assets:169167164000
Other undisclosed assets110   
TOTAL ASSETS:181180180515
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities111111
Accounts payable111011
Accrued liabilities000001
Debt0   (0)(0)
Due to related parties000200
Other undisclosed current liabilities   000
Total current liabilities:111322
Noncurrent Liabilities
Long-term debt and lease obligation2     
Operating lease, liability2
Other undisclosed noncurrent liabilities5623   
Total noncurrent liabilities:7623   
Total liabilities:8724322
Stockholders' equity
Stockholders' equity attributable to parent, including:1721731562(1)3
Common stock000000
Additional paid in capital229226193302525
Accumulated other comprehensive income (loss)(0)00010
Accumulated deficit(57)(53)(38)(28)(26)(22)
Other undisclosed stockholders' equity attributable to parent  (0)   
Total stockholders' equity:1721731562(1)3
TOTAL LIABILITIES AND EQUITY:181180180515

Income statement (P&L) ($ in millions)

9/30/2019
TTM
6/30/2019
6/30/2018
6/30/2017
6/30/2016
12/31/2014
Revenues
(Revenue, Net)
    0 
Cost of revenue
(Cost of Goods and Services Sold)
    (0)(0)
Gross profit:    0(0)
Operating expenses(10)(11)(8)(2)(2)(2)
Operating loss:(10)(11)(8)(2)(2)(2)
Nonoperating income (expense)(10)(7)(1)0(0)(0)
Foreign currency transaction gain (loss), before tax0(0)00(0)(0)
Debt instrument, convertible, beneficial conversion feature     1
Interest and debt expense0(0)(0)(0)(0)(0)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes(0)000  
Loss from continuing operations before equity method investments, income taxes:(20)(18)(9)(2)(2)(3)
Other undisclosed income from continuing operations before income taxes    00
Loss from continuing operations before income taxes:(20)(18)(9)(2)(2)(3)
Income tax benefit  0000
Net loss available to common stockholders, diluted:(20)(18)(9)(2)(2)(2)

Comprehensive Income ($ in millions)

9/30/2019
TTM
6/30/2019
6/30/2018
6/30/2017
6/30/2016
12/31/2014
Net loss:(20)(18)(9)(2)(2)(2)
Other comprehensive income (loss)(0)(0)(0)(0)0(0)
Comprehensive loss:(20)(18)(9)(2)(2)(3)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(60)    1
Comprehensive loss, net of tax, attributable to parent:(80)(18)(9)(2)(2)(2)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: